Cardiome Pharma (CRME) Tops Q1 EPS by 15c

Cardiome Pharma (NASDAQ: CRME) reported Q1 EPS of ($0.06), $0.15 better than the analyst estimate of ($0.21). Revenue for the quarter came in at $7.1 million versus the consensus estimate of $6.34 million.

For earnings history and earnings-related data on Cardiome Pharma (CRME) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79